BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Khayat HR, Kamal EM, El-Sayed MH, El-Shabrawi M, Ayoub H, RizK A, Maher M, El Sheemy RY, Fouad YM, Attia D. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther. 2018;47:838-844. [PMID: 29349793 DOI: 10.1111/apt.14502] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 El-araby HA, Behairy BE, El-guindi MA, Adawy NM, Allam AA, Sira AM, Khedr MA, Elhenawy IA, Sobhy GA, Basiouny HEDM, Salem ME, Abdel-aziz SA, Fouad OA, Ayoub BA. Generic sofosbuvir/ledipasvir for the treatment of genotype 4 chronic hepatitis C in Egyptian children (9–12 years) and adolescents. Hepatol Int 2019;13:706-14. [DOI: 10.1007/s12072-019-09985-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
2 Yang CHT, Goel A, Ahmed A. Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C. Adolesc Health Med Ther 2018;9:103-10. [PMID: 30104913 DOI: 10.2147/AHMT.S147896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
4 Rogers ME, Balistreri WF. Cascade of care for children and adolescents with chronic hepatitis C. World J Gastroenterol 2021; 27(12): 1117-1131 [PMID: 33828389 DOI: 10.3748/wjg.v27.i12.1117] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Gayam V, Khalid M, Mandal AK, Hussain MR, Mukhtar O, Gill A, Garlapati P, Shrestha B, Guss D, Sherigar J, Mansour M, Mohanty S. Direct-Acting Antivirals in Chronic Hepatitis C Genotype 4 Infection in Community Care Setting. Gastroenterology Res 2018;11:130-7. [PMID: 29707080 DOI: 10.14740/gr999w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
6 Nwaohiri A, Schillie S, Bulterys M, Kourtis AP. Hepatitis C virus infection in children: How do we prevent it and how do we treat it? Expert Rev Anti Infect Ther 2018;16:689-94. [PMID: 30091654 DOI: 10.1080/14787210.2018.1509707] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
7 El-sayed MH, Indolfi G. Hepatitis C Virus Treatment in Children: A Challenge for Hepatitis C Virus Elimination. Semin Liver Dis 2020;40:213-24. [DOI: 10.1055/s-0040-1708812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Fouad HM, Ahmed Mohamed A, Sabry M, Abdel Aziz H, Eysa B, Rabea M. The Effectiveness of Ledipasvir/Sofosbuvir in Youth With Genotype 4 Hepatitis C Virus: A Single Egyptian Center Study. Pediatr Infect Dis J. 2019;38:22-25. [PMID: 30234791 DOI: 10.1097/inf.0000000000002189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
9 El-Khayat H, Kamal EM, Yakoot M, Gawad MA, Kamal N, El Shabrawi M, Sameh Y, Haseeb A, Fouad Y, Attia D. Effectiveness of 8-week sofosbuvir/Ledipasvir in the adolescent chronic hepatitis C-infected patients. Eur J Gastroenterol Hepatol. 2019;31:1004-1009. [PMID: 30676473 DOI: 10.1097/meg.0000000000001360] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
10 Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:477-487. [PMID: 30982721 DOI: 10.1016/s2468-1253(19)30046-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 17.7] [Reference Citation Analysis]
11 Fu Z, Dong C, Ge Z, Wang C, Zhang Y, Shen C, Li J, Zhu C, Wang Y, Huang P, Yue M. High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis. Front Med (Lausanne) 2021;8:608760. [PMID: 34169081 DOI: 10.3389/fmed.2021.608760] [Reference Citation Analysis]
12 Indolfi G, Giometto S, Serranti D, Bettiol A, Bigagli E, De Masi S, Lucenteforte E. Systematic review with meta-analysis: the efficacy and safety of direct-acting antivirals in children and adolescents with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2020;52:1125-1133. [PMID: 32809230 DOI: 10.1111/apt.16037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
13 Abdel Ghaffar TY, El Naghi S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, Moafy M. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C Genotype 4. J Viral Hepat. 2019;26:263-270. [PMID: 30380158 DOI: 10.1111/jvh.13032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
14 Serranti D, Dodi I, Nicastro E, Cangelosi AM, Riva S, Ricci S, Bartolini E, Trapani S, Mastrangelo G, Vajro P, D'Antiga L, Resti M, Indolfi G. Shortened 8-Week Course of Sofosbuvir/Ledipasvir Therapy in Adolescents With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr. 2019;69:595-598. [PMID: 31335836 DOI: 10.1097/mpg.0000000000002449] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
15 El-Karaksy H, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, El-Koofy N, El-Shabrawi M, Ghita H, Baroudy S, Okasha S. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67:626-630. [PMID: 30216203 DOI: 10.1097/mpg.0000000000002101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 8.3] [Reference Citation Analysis]
16 Pokorska-Śpiewak M, Dobrzeniecka A, Aniszewska M, Marczyńska M. Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project. J Clin Med 2021;10:4176. [PMID: 34575286 DOI: 10.3390/jcm10184176] [Reference Citation Analysis]
17 El-Shabrawi MHF, Kamal NM, El-Khayat HR, Kamal EM, AbdElgawad MMAH, Yakoot M. A pilot single arm observational study of sofosbuvir/Ledipasvir (200 + 45 mg) in 6- to 12- year old children. Aliment Pharmacol Ther. 2018;47:1699-1704. [PMID: 29696674 DOI: 10.1111/apt.14677] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
18 El-Baraky IA, Abbassi MM, Ebied FS, Hassany M, Sabry NA, El-Sayed MH. Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients. Clin Res Hepatol Gastroenterol 2021;45:101747. [PMID: 34186262 DOI: 10.1016/j.clinre.2021.101747] [Reference Citation Analysis]
19 Makhlouf NA, Abdelmalek MO, Ibrahim ME, Abu-Faddan NH, Kheila AE, Mahmoud AA. Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness. J Pediatric Infect Dis Soc. 2021;10:7-13. [PMID: 32060510 DOI: 10.1093/jpids/piaa006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Serranti D, Nebbia G, Cananzi M, Nicastro E, Di Dato F, Nuti F, Garazzino S, Silvestro E, Giacomet V, Forlanini F, Pinon M, Calvo PL, Riva S, Dodi I, Cangelosi AM, Antonucci R, Ricci S, Bartolini E, Mastrangelo G, Trapani S, Lenge M, Gaio P, Vajro P, Iorio R, D'Antiga L, Indolfi G. Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study. J Pediatr Gastroenterol Nutr. 2021;72:95-100. [PMID: 32810039 DOI: 10.1097/mpg.0000000000002900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
22 El-Khayat H, Yakoot M, El-Shabrawi M, Fouad Y, Attia D, Kamal EM. Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant? Pediatr Infect Dis J 2021;40:11-5. [PMID: 32925546 DOI: 10.1097/INF.0000000000002894] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. Pediatr Infect Dis J 2020;39:e59-65. [PMID: 32345829 DOI: 10.1097/INF.0000000000002717] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kamal EM, El-Shabrawi M, El-Khayat H, Yakoot M, Sameh Y, Fouad Y, Attia D. Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. Liver Int. 2020;40:319-323. [PMID: 31758735 DOI: 10.1111/liv.14308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
25 Alqahtani SA, Colombo MG. Treating paediatric hepatitis C in the era of direct-acting antiviral agents. Liver Int 2021;41:1189-200. [PMID: 33533543 DOI: 10.1111/liv.14810] [Reference Citation Analysis]